Iliofemoral arteries were explanted 5 and 11 days after implantation of vascular smooth muscle-BAG cells. Artery segments were fixed in 1.25% glutaraldehyde in PBS for 15 minutes, rinsed in PBS twice, and placed in X-gal solution at 37°C for 8 hours. Fixed stained segments were embedded in glycol methacrylate, and 7-,gm sections were cut for microscopic analysis.
Results

Expression of /3-Galactosidase in Vascular Smooth Muscle Cells
Genetically modified vascular smooth muscle cells were derived by incubation with the BAG retroviral vector, which confers ,3-galactosidase expression and resistance to the aminoglycoside antibiotic G418. Cells surviving selection in G418 (0.7 mg/ml) were analyzed for ,3-galactosidase activity. Uninfected vascular smooth muscle cells did not show endogenous P-galactosidase activity, as determined by blue coloration after incubation with the X-gal substrate ( Figure 1A ). In contrast, nearly all of the G418-resistant cells exhibited blue staining ( Figure 1B) . The identity of these vascular smooth muscle cells was confirmed by immunofluorescence using monoclonal antibody against smooth muscle a-actin, which is specific for vascular smooth muscle cells. A fibrillar pattern of fluorescence characteristic of the actin cytoskeletal network was observed in the vascular smooth muscle-BAG cells (Figures 2A and  2B ), whereas a porcine endothelial cell line did not exhibit fluorescence using this a-actin antibody (Figures 2C and 2D ). In Figure  1C ), arteries explanted from animals receiving vascular smooth muscle-BAG cells revealed extensive blue coloration after X-gal staining, which is indicative of ,B-galactosidase activity ( Figure 1D ). These sections are representative of a total of four arterial segments examined from two independent animals. Specimens were derived from these animals on days 5 and 11, respectively. The gross arterial specimen showed staining of the luminal surface over the area of cell seeding, with a line of demarcation at the site of balloon inflation. No staining was observed in the distal artery or elsewhere (Figure iD) . Microscopic analysis revealed no staining of control arteries (Figure 1E ), but f-galactosidase-expressing cells were found in seeded arteries in both the intimal and medial layers ( Figure 1F) . A small degree of intimal hyperplasia was present on the luminal side of the internal elastic lamina.
Discussion
This study demonstrates the feasibility of expressing recombinant genes in the vasculature using smooth muscle cells introduced by catheterization. In these experiments, both the medial and luminal layers contained vascular smooth muscle-BAG cells. In the intimal region, several layers of modified smooth muscle cells were observed, raising the possibility that the vascular smooth muscle-BAG cells continued to proliferate in vivo after implantation. In part, this proliferation may reflect the use of actively replicating cells for implantation. It is also possible that mitogenic factors were stimulated as a result of vessel injury produced by catheterization. In either case, this observation suggests that genetically modified vascular smooth muscle cells maintain their ability to proliferate in vivo. Endogenous smooth muscle cells, which do not express 3-galactosidase, were also observed within the zone of intimal proliferation, suggesting that the behavior of the recombinant cells was similar to that of the native cells. In contrast to earlier studies using endothelial cells,23 vascular smooth muscle-BAG cells were also observed in the media of the vessel wall. Analysis of the vessel wall in previous studies has shown disruption of the internal elastic lamina after denudation and inflation of the balloons. It is likely that this allowed the penetration of vascular smooth muscle-BAG cells into the media, where attachment may be facilitated by intercellular adhesion molecules.
Once attached to the wall, it is possible that cellcontact or growth-inhibitory factors stopped proliferation of vascular smooth muscle-BAG cells in the media. In these experiments, four vessel segments were examined in two independent animals at days 5 and 11. Because the Yucatan minipig strain has been recently outbred, longer time periods were not examined because they would increase the likelihood of immune rejection.
The vascular smooth muscle cells used in these experiments were modified to express recombinant genes by infecting them with an amphotropic retroviral vector. One potential disadvantage in using retroviral vectors is the possibility of generating replication-competent helper virus either in the virus stock used to infect cells or within recipient cells after infection. 
Appendix
Glossary and Explanation of Techniques G418 resistance-The aminoglycoside antibiotic geneticin (G418) is toxic to eukaryotic cells at concentrations ranging from 0.5 to 2.0 mg/ml. This drug can be inactivated by the introduction of a bacterial enzyme, the neomycin resistance gene, into eukaryotic cells. This gene encodes a phosphotransferase enzyme that modifies the G418 molecule. The retroviral vector used in these experiments contains both /-galactosidase and the neomycin-resistance gene.
When this retrovirus is introduced into vascular smooth muscle cells, cells that can express this gene will survive selection in G418 (0.7 mg/ml) for 3 weeks. Nontransduced vascular smooth muscle cells are completely eliminated by treatment with G418 (0.7 mg/ml) within 10 days. This selection can therefore be used to ensure that the relevant recombinant genes have been stably incorporated into the vascular smooth muscle cells.
Lipofection 
